AnGes, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMGXF research report →
Price Chart
About the company
AnGes, Inc. , a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characterized by impaired blood circulation in the legs.
- CEO
- Ei Yamada
- IPO
- 2017
- Employees
- 56
- HQ
- Ibaraki, OS, JP
Get TickerSpark's AI analysis on AMGXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $142.50M
- P/E
- -3.57
- PEG
- -0.02
- P/S
- 13.98
- P/B
- 65.69
- EV/EBITDA
- -2.52
- Div Yield
- 0.00%
- Gross Margin
- 41.38%
- Op Margin
- -621.79%
- Net Margin
- -402.50%
- ROE
- -163.39%
- ROIC
- -575.91%
Latest fiscal year · YoY change
- Revenue
- $874.88M+35.9%
- Gross Profit
- $320.66M+29.5%
- Op Income
- $-5,149,882,816
- Net Income
- $-5,127,739,549+81.8%
- EPS
- $-14.45+88.6%
- OCF Growth
- +13.0%
- FCF Growth
- +13.8%
- 52W High
- $0.36
- 52W Low
- $0.34
- 50D MA
- $0.36
- 200D MA
- $0.36
- Beta
- 0.64
- RSI (14)
- 100
- Avg Volume
- 144
No earnings-call transcripts are available for AMGXF yet.
- Free Float
- 97.9%
- Shares Outstanding
- 395.63M
- Float Shares
- 387.13M
Our AMGXF coverage
Recent articles, reports, and earnings notes.
No research on AMGXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMGXF report →